A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Study acronym: PERSISTCRSwNP2
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 1 → 4 locations
  2. Recruitment opened Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 31, 2026 to Sep 3, 2026
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 5 of 8 entries
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.
Trial Details
NCT Number NCT07782957
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Nasal Polyps
Related terms Nasal Polyps, Paranasal Sinus Diseases
Enrollment 218 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov